Drug: Rapamycin

What It Is

Rapamycin is a compound first isolated from a soil bacterium found on Easter Island, which is where its name comes from, the island being known locally as Rapa Nui. As the drug sirolimus it has been used in medicine for decades, chiefly to suppress the immune system after an organ transplant so the body does not reject the new organ, and to coat the stents that hold coronary arteries open. Close relatives, everolimus and temsirolimus, are used in certain cancers and in the rare disease tuberous sclerosis. Rapamycin is an established prescription medicine with defined, approved uses.

The reason it has become the most discussed molecule in aging research is separate from any of that. Rapamycin acts on a growth-control pathway called mTOR, and dialing that pathway down is the intervention the whole longevity case rests on. That has led to a large and growing off-label use, people taking rapamycin in the hope of slowing their own aging, well ahead of any human trial. This page is education, not a protocol, and it names no dose.

Anatomy

1The mTOR pathway

mTOR, the mechanistic target of rapamycin, is a master growth switch inside every cell. It senses nutrients and growth signals and, when they are plentiful, drives the cell to build proteins and grow while holding back cellular recycling. Turning mTOR down slows growth and steps up autophagy, the process that clears out worn-out cellular parts. This is the pathway the whole longevity case runs through.

2Sirolimus, the original drug

Sirolimus is rapamycin as a licensed medicine. It is given orally to prevent kidney transplant rejection and to treat the rare lung disease lymphangioleiomyomatosis, and it coats drug-eluting cardiac stents. It is the form with the longest human safety record, gathered mostly in transplant patients taking it continuously at doses set to suppress the immune system.

3Everolimus and the analogues

Everolimus and temsirolimus are chemical relatives of rapamycin, the class often called rapalogs. Everolimus is approved for several cancers, for tuberous sclerosis, and in transplant medicine. In aging research the low-dose, short-course use of everolimus is what produced the human immune findings, at doses well below those used to prevent transplant rejection.

How It Works

Rapamycin works by inhibiting mTOR complex 1, the branch of the mTOR pathway that governs cell growth. It does this indirectly: the drug first binds a small intracellular protein called FKBP12, and that pair then latches onto mTOR complex 1 and shuts much of its activity down. When mTOR complex 1 is active, the cell reads it as a signal that nutrients are abundant and growth is safe, so it builds proteins, grows, and suppresses recycling. Inhibiting it reverses this: the cell lowers its building and switches on autophagy, the housekeeping process that breaks down and recycles damaged components, reproducing much of the cellular state that fasting produces.

That connection is why rapamycin is central to aging biology. Nutrient sensing is one of the recognized hallmarks of aging, and mTOR is the central node in it, so a drug that turns the node down is a direct test of the idea that dialing back growth signaling slows the aging process. For the wider picture of the mTOR pathway and where it fits among the other drivers of aging, see the biology of aging. Prolonged or higher-dose rapamycin also disturbs a second complex, mTOR complex 2, and that second effect is tied to the drug's influence on blood sugar and insulin, which matters for the metabolic risks below.

What It Does

Rapamycin's evidence divides sharply between animals and people.

The animal record is the strongest in longevity research. In the National Institute on Aging Interventions Testing Program, which tests compounds in genetically diverse mice at three separate laboratories to screen out fluke results, rapamycin extended lifespan and the result held up to replication, even when treatment began at roughly the human equivalent of age 60. This is why the mouse findings sit at the top of the ladder below: no other longevity molecule has an animal record this consistent. It remains a mouse result, a strong reason to study the drug in people, not a demonstration that it works in them.

The human evidence sits lower because it measures immunity and feasibility, not lifespan. No completed trial has tested whether rapamycin extends human life or healthspan. The signals that exist are narrow immune findings in adults over 65, measured over weeks to a year, and one large phase-3 trial of the mTOR inhibitor RTB101 on its own missed its main infection endpoint, which holds them at promising, not settled. The physical-function trials in healthy people are small and early.

The approved uses are separate again. As sirolimus, rapamycin is licensed for organ-transplant rejection and a rare lung disease, and its relatives everolimus and temsirolimus for certain cancers and tuberous sclerosis. Those uses account for most of what is known about the drug's side effects, because they run on continuous dosing set to act strongly on the immune system or a tumor. None of them is aging.

The Research & Studies

Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.

How it works

Rapamycin inhibits mTORC1, mimicking mild fasting and switching on autophagyStrong · mixed

In plain terms

Rapamycin turns down mTOR, the master switch a cell uses to sense nutrients and balance growth against recycling. Turning it down mimics mild fasting and steps up autophagy, the recycling of worn-out parts.

In detail

Rapamycin (sirolimus) forms a complex with the 12 kDa FK506-binding protein (FKBP12) that binds and inhibits mTOR complex 1. mTORC1 integrates signals from amino acids, growth factors and energy status to drive ribosome biogenesis, protein and lipid synthesis, and cell growth, and it suppresses macroautophagy. Inhibiting mTORC1 therefore lowers anabolic activity and de-represses autophagy, reproducing much of the cellular state that nutrient scarcity and caloric restriction produce. Prolonged or higher-dose exposure also affects the second complex, mTORC2, which is relevant to the metabolic effects seen with the drug.

The study · 1

Saxton and Sabatini, mTOR Signaling in Growth, Metabolism, and Disease · Cell 2017;169(2):361-371

Respiratory Infection

A low-dose mTOR inhibitor cut respiratory infections in older adults over the following yearModerate

In plain terms

In a larger follow-up trial, a low-dose mTOR inhibitor lowered the number of respiratory infections in older adults across a year. It is the strongest human signal that turning mTOR down can support immune function with age.

In detail

Mannick and colleagues (2018) randomized 264 older adults to combinations of the mTOR inhibitor RTB101 and everolimus or to placebo and followed respiratory tract infections over a year. The regimen that combined low doses of both drugs reduced the rate of laboratory-confirmed respiratory infections and was associated with an upregulated antiviral gene signature, extending the earlier vaccine finding to a clinical infection endpoint.

The study · 1

Mannick et al., TORC1 inhibition enhances immune function and reduces infections in the elderly · Sci Transl Med 2018;10(449):eaaq1564

Blood Sugar

Chronic rapamycin caused insulin resistance in mice by disrupting mTORC2Moderate · risk

In plain terms

Long-term rapamycin can cause insulin resistance, and in mice this comes from hitting a second mTOR complex. It suggests the metabolic downside and the longevity benefit may run through different branches of the pathway.

In detail

Lamming and colleagues (2012) showed that chronic rapamycin in mice disrupts mTOR complex 2 (mTORC2) in addition to mTORC1, and that the loss of mTORC2 signaling in the liver drives the glucose intolerance and insulin resistance seen with the drug. Because lifespan extension is attributed mainly to mTORC1 inhibition, the work raised the prospect that the metabolic cost and the longevity benefit are, at least in principle, separable.

The study · 1

Lamming et al., Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity · Science 2012;335(6076):1638-1643

Rapamycin left mice glucose intolerant yet still insulin sensitiveModerate · mixed

In plain terms

Rapamycin's effect on blood sugar in mice is mixed: it worsens glucose handling on one test while preserving insulin sensitivity on another. The metabolic picture is more complicated than a single label.

In detail

Lamming and colleagues (2013) found that young and old genetically heterogeneous mice fed rapamycin were glucose intolerant on a glucose challenge yet stayed insulin sensitive, an uncoupling that does not match the usual pattern of type 2 diabetes. The finding sharpens the metabolic question rather than dismissing it, because glucose intolerance, raised triglycerides and cholesterol are also documented in people who take the drug for organ transplant.

The study · 1

Lamming et al., Young and old genetically heterogeneous HET3 mice on a rapamycin diet are glucose intolerant but insulin sensitive · Aging Cell 2013;12(4):712-718

Immune Function

Six weeks of an mTOR inhibitor raised older adults' flu-vaccine antibody response about 20%Emerging

In plain terms

A short course of an mTOR inhibitor improved how well older adults responded to a flu vaccine. This is a narrow human immune finding, not evidence about lifespan.

In detail

Mannick and colleagues (2014) randomized 218 adults aged 65 and older to low doses of the rapamycin analogue everolimus or placebo for six weeks before seasonal influenza vaccination. Low-dose everolimus improved the antibody response to the vaccine by roughly 20% and reduced the proportion of exhausted, senescent immune cell subsets, suggesting mTOR inhibition can partially reverse aspects of immune aging. The doses were lower and given for a shorter period than those used to prevent transplant rejection.

The study · 1

Mannick et al., mTOR inhibition improves immune function in the elderly · Sci Transl Med 2014;6(268):268ra179

Longevity And Mortality

Rapamycin started late raised mouse lifespan about 9% in males and 14% in femalesPreliminary

In plain terms

Rapamycin is the most reliable drug known for extending lifespan in mice, and it works even when started in old age. The finding has been repeated in a rigorous multi-site program, which is why it is the flagship animal result.

In detail

Harrison and colleagues (2009) reported that rapamycin fed to genetically heterogeneous mice starting at 600 days of age extended median and maximal lifespan in both sexes, a striking result because the treatment began late in life. Miller and colleagues (2011) confirmed lifespan extension with rapamycin in the same multi-site Interventions Testing Program while resveratrol and simvastatin did not extend life, strengthening the finding through independent replication. The Interventions Testing Program tests compounds at three sites in a genetically diverse mouse population specifically to reduce false positives.

The studies · 2

Harrison et al., Rapamycin fed late in life extends lifespan in genetically heterogeneous mice · Nature 2009;460(7253):392-395

Miller et al., Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice · J Gerontol A Biol Sci Med Sci 2011;66(2):191-201

A threefold higher dose extended mouse lifespan about 23% in males and 26% in femalesPreliminary

In plain terms

The mouse lifespan effect grows at higher doses and differs between males and females, which shows the benefit is dose related and is not simply the same as eating less.

In detail

Miller and colleagues (2014) tested higher rapamycin doses in genetically heterogeneous mice and found larger lifespan gains than at the original dose, with a clear dose-response and consistent sex differences in the size of the effect. The authors also reported that the metabolic changes accompanying rapamycin differed from those produced by dietary restriction, indicating the two interventions extend life through at least partly separate routes.

The study · 1

Miller et al., Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction · Aging Cell 2014;13(3):468-477

Cognition

Chronic rapamycin improved learning and lowered anxiety-like behavior in micePreliminary

In plain terms

In mice, long-term rapamycin improved learning and reduced anxiety-like behavior. It is an early animal signal for the brain, not a demonstrated effect in people.

In detail

Halloran and colleagues (2012) gave mice chronic rapamycin across the lifespan and found improvements on tests of learning and memory together with reduced anxiety-like and depressive-like behaviors, accompanied by higher brain levels of several neurotransmitters. The work is an early mechanistic lead for effects of mTOR inhibition on the aging brain rather than evidence of cognitive benefit in humans.

The study · 1

Halloran et al., Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice · Neuroscience 2012;223:102-113

Muscle And Strength

Eight weeks of rapamycin showed no clear physical-performance gain in healthy older adultsPreliminary · no effect

In plain terms

A small, short human trial found rapamycin was tolerable in healthy older adults but showed no clear improvement in physical function. Human longevity trials with physical-function endpoints are only now emerging.

In detail

Kraig and colleagues (2018) randomized 25 healthy older adults to eight weeks of rapamycin or placebo to test feasibility and safety, tracking immune, physical performance and cognitive measures. The drug was tolerated without serious adverse events, and no clear change was seen in physical performance, cognition or most immune measures in this small, short study, which was designed to establish feasibility rather than to detect an effect. The one consistent laboratory signal was statistically significant decrements in several red-cell measures, including hemoglobin, hematocrit and red blood cell count, which the authors judged not clinically significant over the short study. Larger off-label efforts such as the PEARL trial, which uses physical-function endpoints, remain preliminary.

The study · 1

Kraig et al., A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort · Exp Gerontol 2018;105:53-69

The Off-Label Gap

Between the strong animal data and the thin human data sits a large off-label experiment. People take rapamycin in the hope of slowing their own aging, usually on an intermittent schedule instead of the continuous dosing used in transplant medicine, reasoning that spacing doses might keep the growth-slowing effect while easing the load on the immune system. That reasoning is a hypothesis drawn from animal work and pharmacology, not a conclusion from any completed human longevity trial.

The human function data that exists is small and short. A feasibility trial gave healthy older adults an eight-week course and found it tolerable, with no clear change in physical performance, cognition, or most immune measures over that span. Its one consistent laboratory signal was a statistically significant drop in several red-cell measures, including hemoglobin, hematocrit, and red blood cell count, which the investigators judged not clinically significant over the short trial. Larger efforts such as the PEARL trial, which uses physical-function endpoints, are still preliminary.

Rapamycin is a prescription immunosuppressant, not a supplement, and no completed human trial establishes a safe or effective dose for slowing aging in a healthy person.

The animal case is strong, the human aging case is early, the best schedule for a healthy person is unknown, and the risks in the Cautions section are already documented. That is the reason the page gives no dose.

Go Deeper

• The biology of aging: where rapamycin and mTOR sit among the hallmarks of aging, and how to read an animal drug result against the human evidence.
• Autophagy: the cellular recycling process rapamycin switches on by inhibiting mTOR, and the mechanism much of the longevity case runs through.
• Peptides: another category where a few approved drugs sit alongside a large off-label market, and how to keep the two apart.
• IV therapy and NAD: a neighboring anti-aging pitch, and the same distinction between moving a marker and changing an outcome.

The Chinese Medicine View

Rapamycin is a product of modern microbiology, isolated in the twentieth century, so there is no classical Chinese entry for it. No historical text assigns it a channel, a temperature, or a flavor, and no traditional formula contains it. What follows places the drug beside the tradition as a lens, not as evidence, and it borrows no classical claim, because none exists. Nothing here suggests any herb or formula reproduces what rapamycin does.

The tradition does reason about the territory the drug acts on. Its mechanism, in cellular terms, mimics a fasting signal: it lowers building in a well-fed cell and clears out what is worn. That sits close to a deep theme in Chinese medicine, the idea in Yang Sheng, the cultivation of life, that moderation and restraint conserve the body's reserves. Classical counsel to stop eating before fullness, and the long practice of periodic simplicity in eating, arrive by observation at the same place nutrient-sensing biology reaches: constant abundance and constant growth signaling are not the state in which a body ages best.

The tradition also holds a caution relevant here. Tonifying, building the body up, is appropriate only when there is a true deficiency and the person can assimilate what is given, and forcing a system harder than its nature intends is understood to deplete rather than restore. A drug that suppresses the immune system and disturbs the transformation of nourishment is, in that framing, a powerful intervention with a cost, to be used where it is warranted rather than reached for freely.

The limit is that this is a way of connecting a modern drug to a framework the tradition has long reasoned about, not a claim that Chinese medicine endorses or explains rapamycin. The classical concepts belong to the tradition as it uses them, and the evidence for the drug stands or falls on the trials, of which the animals have many and healthy humans have almost none.

Cautions

Everything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.

At treatment doses, sirolimus commonly caused mouth ulcers, raised cholesterol and diarrhea

McCormack and colleagues (2011) randomized 89 women with lymphangioleiomyomatosis to sirolimus or placebo for a year. Sirolimus stabilized lung function during treatment, and the trial documented its adverse-effect profile: mucositis (mouth ulcers), gastrointestinal effects such as diarrhea and nausea, acneiform rash, hypercholesterolemia and peripheral edema occurred more often than with placebo. The lung-function benefit was lost after the drug was stopped, underlining that these effects accompany continuous therapeutic dosing.McCormack et al., Efficacy and safety of sirolimus in lymphangioleiomyomatosis

A prescription immunosuppressant, not a supplement

Rapamycin is a prescription drug whose primary action is to suppress the immune system. At the doses used in transplant medicine it lowers immune defenses enough to raise the risk of infections, including serious ones, and it requires blood-level monitoring and medical oversight. Whatever the longevity hopes attached to it, it belongs in the hands of a clinician who can weigh that risk for a given person.

Infection risk

Because it dampens immune function, rapamycin can make infections more likely and harder to clear. This is the central trade-off of the drug and the reason the aging research uses lower, spaced doses in the hope of reducing it. Whether intermittent dosing avoids meaningful immunosuppression in a healthy person is not established.

Mouth ulcers and impaired wound healing

Mouth ulcers, or mucositis, are among the most common side effects, and rapamycin slows wound healing, which is why surgeons often pause it around operations. Anyone facing surgery or dealing with a wound needs a clinician to manage the drug, not a schedule found online.

Effects on blood sugar and lipids

Rapamycin can raise cholesterol and triglycerides and can worsen glucose handling, effects tied to its action on the second mTOR complex. In animals the metabolic picture is mixed, and in transplant patients these changes are well documented. They are part of the risk that any longevity use has to account for.

Drug interactions

Rapamycin is processed by liver enzymes that many other drugs and even grapefruit affect, so its blood levels can swing up or down when combined with common medications. This is one more reason its use requires a prescriber who knows the full medication list, not self-management.

Not a do-it-yourself longevity drug

There is no completed human trial that establishes a safe and effective rapamycin dose or schedule for slowing aging in a healthy person. The animal evidence is strong and the human aging research is early and ongoing. If rapamycin interests you, the appropriate step is a conversation with a knowledgeable clinician who can weigh the risks, not a purchase and a protocol.

Start slow, be smart, read the research, and consult a professional if you have any concerns. This is here to inform your choice, not make it for you.

Common Questions

Does rapamycin actually extend lifespan?

In mice, yes, and more reliably than any other drug tested, including when it is started late in life, with the result replicated across independent laboratories. In people, it has not been shown to extend lifespan or healthspan. No completed human trial measures that, and the human studies so far are small and short, looking at immune markers, feasibility and physical function rather than years of life. The animal record is strong; the human aging benefit is promising but not established.

Is rapamycin approved for anything?

Yes. As sirolimus it is approved to prevent organ transplant rejection and to treat the rare lung disease lymphangioleiomyomatosis, and it coats coronary stents. Its relatives everolimus and temsirolimus are approved for several cancers and for tuberous sclerosis. These are established, valuable uses with decades of human experience behind them. None of them is aging: the approved uses rest on the drug's ability to suppress the immune system or slow tumor growth, which is a different purpose from slowing aging in a healthy person.

Why do some people take rapamycin off-label for aging?

They are extrapolating from the animal longevity data, which is strong, and often use an intermittent schedule instead of the continuous transplant dosing, reasoning that spacing doses might capture the growth-slowing effect while sparing the immune system. That rationale is a hypothesis based on animal work and pharmacology, not a conclusion from a completed human longevity trial. The best dose and schedule for a healthy person are not established, which is why this page describes the practice without giving a dose.

What are the main risks of rapamycin?

The central one is immunosuppression, which raises the risk of infections. Common side effects include mouth ulcers, and the drug slows wound healing, which matters around surgery. It can also raise cholesterol and triglycerides and worsen glucose handling, and its blood levels interact with many other drugs and with grapefruit. These risks are well documented from its approved uses at treatment doses. Whether the lower, intermittent doses explored for aging reduce them is one of the open questions the research is still working on.

Can a Chinese herb or formula do what rapamycin does?

No, and this page makes no such claim. Rapamycin is a specific modern drug that inhibits the mTOR pathway, and no herb or formula has been shown to reproduce that action or its effects. What the Chinese medicine tradition offers here is a lens, not a substitute: its long emphasis on moderation, on not overfilling the body, and on restraint rather than forcing growth aligns with what nutrient-sensing biology has found, but that is a resonance of ideas, not an equivalent treatment. The evidence for the drug rests on its own trials.